Fas Ligand Cleavage regulates ocular homeostasis and glaucoma
Fas 配体裂解调节眼稳态和青光眼
基本信息
- 批准号:10550147
- 负责人:
- 金额:$ 60.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressApoptosisApoptoticAstrocytesBindingBlindnessCD95 AntigensCause of DeathCell DeathCellsCessation of lifeChimera organismChronic DiseaseDangerousnessDataDefectDevelopmentDiseaseEffector CellEmbryoEnvironmentEquilibriumExtracellular DomainEyeEye diseasesFamilyFluorochromeGene ExpressionGene TargetingGenetic TranscriptionGlaucomaGlial Fibrillary Acidic ProteinGoalsGrantHomeostasisImmuneInfiltrationInflammationInflammatoryInjectionsIntegral Membrane ProteinLengthLigandsLinkMediatingMediatorMembraneMetalloproteasesMicrospheresModelingMonitorMorulaMuller&aposs cellMusMutateMutationNeurogliaOcular PathologyOnset of illnessOptic DiskOptic NerveOutcomePathogenesisPathologicPathologyPathway interactionsPatientsPeptide HydrolasesPreventionProcessProductionProtein IsoformsProteinsRegulationResearchRetinaRetinal Ganglion CellsRoleSignal PathwaySignal TransductionSiteSourceTIMP1 geneTNF geneTamoxifenTherapeuticTimeTissue Inhibitor of Metalloproteinase-1TissuesTransfectionTumor Necrosis Factor Ligand Superfamily Member 6Vascular Endothelial Cellcell typechemokineconstitutive expressioncytokineimprovedinducible Creinsightintravitreal injectionmacrogliamembrane activityneurotoxicnew therapeutic targetnoveloverexpressionpreventprogramsreceptorrecruitsortasesystemic autoimmune diseasetherapeutic targettoolvector
项目摘要
The type II transmembrane protein Fas ligand (Fasl) was first identified as a death receptor ligand that induced
Fas+ target cells to undergo apoptosis. As such, its constitutive expression in the eye has historically been linked
to the phenomenon of immune privilege and its ability to kill activated eye-infiltrating Fas+ effector cells, or eye-infiltrating
Fas+ vascular endothelial cells. However, this notion is confounded by the fact that many non-hematopoietic
cell types in the eye, including retinal ganglion cells (RGCs), constitutively express Fas. In fact,
Fasl-mediated destruction of RGCs is a key factor in glaucoma pathogenesis, either by direct killing of RGCs
and/or by inducing the production of proinflammatory chemokines by Fas+ glial cells (eg. astrocytes), that recruit
proinflammatory cells to the retina and thereby causing neurotoxic inflammation. This apparent conundrum can
be explained if one accepts our hypothesis that constitutive metalloproteinase-mediated cleavage of
membraned-bound Fasl (mFasL), releases a soluble fragment (sFasL) that opposes the neurotoxic activity of
mFasL. This premise is supported by preliminary data showing: (a) mice with a gene-targeted mutation of Fasl
that eliminates this Fasl cleavage site (mFaslmice) develop accelerated glaucoma in spontaneous and
inducible glaucoma models; {b} in healthy eyes, retinal Fasl is constitutively cleaved, but in glaucomatous eyes,
retinal Fasl is membrane-bound; and (c) intravitreal injection of an AAV2-sFasL vector prior to disease onset
can prevent the development of glaucoma, while injection of AAV2-sFasL after disease onset can reverse
functional defects. Together, these data point to Fasl as an important therapeutic target for patients with
glaucoma. However, a number of key questions remain unanswered and will be addressed by the proposed 3
specific aims: (Aim 1) When and how is Fasl cleavage suppressed during the development and progression of
glaucoma and how do ADAM10 and TIMP1 in regulate Fasl cleavage ?; (Aim 2) To what extent does the direct
engagement of Fas, expressed by astrocytes and/or RGCs, contribute to the development of glaucoma?; and
(Aim 3) Can sFasL directly engage Fas to elicit a protective gene expression program? Our research strategy
will involve both accepted and novel experimental tools, including (a) sortase-tagged-Fasl mice (provide by Dr.
Ploegh}, that will greatly facilitate our ability to monitor mFasL vs sFasL protein levels in the eye, {b} Fas-flexed
mice crossed to RGC- and astrocyte/muller-specific ere-deleter lines, that will allow us to identify the importance
of these cells in the development of glaucoma; (c) allophenic (tetraparental) chimeric mice made by fusing Fas+
and Fasn•9 embryos, that will allow us to distinguish direct and indirect effects of Fasl engagement in the context
of glaucoma, and {d} AAV2-sFasL vectors that will allow us to determine if sFasL functions independently of
mFasL. The mechanistic insights gained from the proposed studies are likely to reveal improved strategies for
the effective manipulation of Fas/Fasl interactions in patients afflicted with glaucoma and other ocular disorders.
II型跨膜蛋白Fas配体(Fasl)首先被鉴定为死亡受体配体,可诱导死亡
Fas+靶细胞发生凋亡。因此,它在眼睛中的组成性表达在历史上一直与
免疫豁免现象及其杀死激活的眼浸润 Fas+ 效应细胞或眼浸润细胞的能力
Fas+血管内皮细胞。然而,这一观点因许多非造血细胞的事实而令人困惑。
眼睛中的细胞类型,包括视网膜神经节细胞 (RGC),组成型表达 Fas。实际上,
Fasl 介导的 RGC 破坏是青光眼发病机制的关键因素,无论是通过直接杀死 RGC
和/或通过诱导 Fas+ 神经胶质细胞(例如星形胶质细胞)产生促炎趋化因子,
促炎细胞到达视网膜,从而引起神经毒性炎症。这个明显的难题可以
如果有人接受我们的假设,即组成型金属蛋白酶介导的裂解
膜结合的 Fasl (mFasL),释放可溶性片段 (sFasL),对抗 神经毒性活性
mFasL。这一前提得到了初步数据的支持,这些数据显示:(a) 具有 Fasl 基因靶向突变的小鼠
消除 Fasl 裂解位点 (mFaslmice) 会加速自发性青光眼的发展
诱导性青光眼模型; {b} 在健康的眼睛中,视网膜 Fasl 是结构性分裂的,但在青光眼的眼睛中,
视网膜 Fasl 是膜结合的; (c) 在疾病发作前玻璃体内注射 AAV2-sFasL 载体
可以预防青光眼的发展,而发病后注射 AAV2-sFasL 可以逆转
功能缺陷。总之,这些数据表明 Fasl 是患有以下疾病的患者的重要治疗靶点:
青光眼。然而,许多关键问题仍未得到解答,将通过拟议的 3
具体目标:(目标 1)Fasl 裂解在疾病的发展和进展过程中何时以及如何受到抑制
青光眼以及 ADAM10 和 TIMP1 如何调节 Fasl 裂解? (目标 2)直接影响到什么程度
星形胶质细胞和/或 RGC 表达的 Fas 的参与会导致青光眼的发展?和
(目标 3)sFasL 能否直接与 Fas 结合以引发保护性基因表达程序?我们的研究策略
将涉及公认的和新颖的实验工具,包括(a)分选酶标记的 Fasl 小鼠(由 Dr.
Ploegh},这将极大地促进我们监测眼睛中 mFasL 与 sFasL 蛋白水平的能力,{b} Fas-flexed
小鼠与 RGC 和星形胶质细胞/苗勒特异性 ere 删除系杂交,这将使我们能够确定重要性
这些细胞在青光眼发展过程中的作用; (c) 通过融合 Fas+ 制成的异体(四亲)嵌合小鼠
和 Fasn•9 胚胎,这将使我们能够区分 Fasl 参与的直接和间接影响
青光眼和 {d} AAV2-sFasL 向量将允许我们确定 sFasL 功能是否独立于
mFasL。从拟议的研究中获得的机制见解可能会揭示改进的策略
有效控制青光眼和其他眼部疾病患者的 Fas/Fasl 相互作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MEREDITH GREGORY-KSANDER其他文献
MEREDITH GREGORY-KSANDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MEREDITH GREGORY-KSANDER', 18)}}的其他基金
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma
Fas 配体裂解调节眼稳态和青光眼
- 批准号:
10374484 - 财政年份:2022
- 资助金额:
$ 60.02万 - 项目类别:
Fas Ligand Cleavage regulates ocular homeostasis and glaucoma
Fas 配体裂解调节眼稳态和青光眼
- 批准号:
10867990 - 财政年份:2022
- 资助金额:
$ 60.02万 - 项目类别:
Regulation of the neuroinflammatory response in autoimmune uveitis
自身免疫性葡萄膜炎神经炎症反应的调节
- 批准号:
10320063 - 财政年份:2021
- 资助金额:
$ 60.02万 - 项目类别:
Regulation of the neuroinflammatory response in autoimmune uveitis
自身免疫性葡萄膜炎神经炎症反应的调节
- 批准号:
10115860 - 财政年份:2021
- 资助金额:
$ 60.02万 - 项目类别:
Regulation of the neuroinflammatory response in autoimmune uveitis
自身免疫性葡萄膜炎神经炎症反应的调节
- 批准号:
10527371 - 财政年份:2021
- 资助金额:
$ 60.02万 - 项目类别:
Uncoupling caspase 8-mediated-apotosis from caspase 8-mediated-inflammation in glaucoma.
将青光眼中 caspase 8 介导的细胞凋亡与 caspase 8 介导的炎症解偶联。
- 批准号:
9919567 - 财政年份:2019
- 资助金额:
$ 60.02万 - 项目类别:
Regulation of vascular leakage in age related macular degeneration
年龄相关性黄斑变性中血管渗漏的调节
- 批准号:
8385057 - 财政年份:2012
- 资助金额:
$ 60.02万 - 项目类别:
Regulation of vascular leakage in age related macular degeneration
年龄相关性黄斑变性中血管渗漏的调节
- 批准号:
8534134 - 财政年份:2012
- 资助金额:
$ 60.02万 - 项目类别:
Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma
DBA/2J 自发性青光眼模型的神经毒性和神经保护
- 批准号:
8237645 - 财政年份:2011
- 资助金额:
$ 60.02万 - 项目类别:
Neurotoxicity and neuroprotection in the DBA/2J spontaneous model of glaucoma
DBA/2J 自发性青光眼模型的神经毒性和神经保护
- 批准号:
8389866 - 财政年份:2011
- 资助金额:
$ 60.02万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 60.02万 - 项目类别:
Research Grant